[{"orgOrder":0,"company":"Trigone Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Oxybutynin","moa":"Muscarinic M1\/M2\/M3 receptor","graph1":"Urology","graph2":"Preclinical","graph3":"Trigone Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Trigone Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Trigone Pharma \/ Not Applicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Imbrium Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"IMB-150","moa":"","graph1":"Urology","graph2":"Preclinical","graph3":"PureTech Health","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ Imbrium Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"PureTech Health \/ Imbrium Therapeutics"},{"orgOrder":0,"company":"Versameb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"VMB-100","moa":"","graph1":"Urology","graph2":"Preclinical","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Versameb \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Not Applicable"},{"orgOrder":0,"company":"Touchlight","sponsor":"Versameb","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"VMB-100","moa":"","graph1":"Urology","graph2":"Preclinical","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Versameb","highestDevelopmentStatusID":"4","companyTruncated":"Touchlight \/ Versameb"},{"orgOrder":0,"company":"Valensa International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Serenoa Repens Extract","moa":"","graph1":"Urology","graph2":"Preclinical","graph3":"Valensa International","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Valensa International \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Valensa International \/ Not Applicable"},{"orgOrder":0,"company":"Versameb","sponsor":"Touchlight","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"VMB-100","moa":"","graph1":"Urology","graph2":"Preclinical","graph3":"Versameb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Versameb \/ Touchlight","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/ Touchlight"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), is being developed to treat chronic stress urinary incontinence (SUI).

                          Brand Name : VMB-100

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 21, 2023

                          Lead Product(s) : VMB-100

                          Therapeutic Area : Urology

                          Highest Development Status : Preclinical

                          Sponsor : Touchlight

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The agreement enables Versameb to use Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology to support the development of novel mRNA-based therapeutics, including VMB-100, addressing unmet needs in urology and oncology.

                          Brand Name : VMB-100

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 01, 2022

                          Lead Product(s) : VMB-100

                          Therapeutic Area : Urology

                          Highest Development Status : Preclinical

                          Sponsor : Versameb

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Strum’s findings validate the effectiveness of an LSESr like Valensa’s USPlus® Pure Lipidosterolic Extract of Serenoa repens (LSESr), commonly known as saw palmetto, for improved quality of life in men with lower urinary tract symptoms (LUTS).

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 30, 2021

                          Lead Product(s) : Serenoa Repens Extract

                          Therapeutic Area : Urology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : VMB-100 has demonstrated first-in-class potential for treatment for Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter. VMB-100 shows therapeutic potential in Stress U...

                          Brand Name : VMB-100

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 04, 2021

                          Lead Product(s) : VMB-100

                          Therapeutic Area : Urology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Under the terms of the agreement, Imbrium is responsible for all future development activities and funding for LYT-503/IMB-150, for which an IND filing is planned for early 2022.

                          Brand Name : LYT-503

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 11, 2021

                          Lead Product(s) : IMB-150

                          Therapeutic Area : Urology

                          Highest Development Status : Preclinical

                          Sponsor : Imbrium Therapeutics

                          Deal Size : $59.5 million

                          Deal Type : Licensing Agreement

                          blank

                          06

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : The in-vitro and animal data suggest that TRG-100 can safely be used for possible intravesical sustained release of Lidocaine and Oxybutynin in the treatment of BPS/IC.

                          Brand Name : TRG-100

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 22, 2021

                          Lead Product(s) : Oxybutynin,Lidocaine

                          Therapeutic Area : Urology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank